Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation

被引:10
作者
Yoon, Jae-Ho [1 ]
Lee, Seok [1 ]
Kim, Hee-Je [1 ]
Lee, Jong-Wook [1 ]
Min, Woo-Sung [1 ]
Chung, Byung Ha [2 ]
Yang, Chul Woo [2 ]
Kim, Yong-Soo [2 ]
Kim, Ji-Il [3 ]
Moon, In Sung [3 ]
Oh, Eun Ji [4 ]
Park, Gyeong-Sin [5 ]
Cho, Seok-Goo [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Blood & Marrow Transplantat Ctr, Dept Hematol, Seoul 137701, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Nephrol, Seoul 137701, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea
[4] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Lab Med, Seoul 137701, South Korea
[5] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Pathol, Seoul 137701, South Korea
关键词
hematopoietic stem cell transplantation; kidney transplantation; post-transplant lymphoproliferative disorder; prognosis; SOLID-ORGAN TRANSPLANTATION; PROGNOSTIC-FACTORS; RITUXIMAB; RECIPIENTS; LYMPHOMAS; PTLD; IMMUNOSUPPRESSION; SURVIVAL; DISEASE;
D O I
10.1111/tri.12328
中图分类号
R61 [外科手术学];
学科分类号
摘要
Post-transplant lymphoproliferative disorder (PTLD) is a major complication caused by immune-suppression after transplantation. Survival outcome is known to be poor and the characteristics are not fully understood because of its rare incidence. This single center retrospective study enrolled 41 adult PTLD patients after kidney-transplantation (KT, n=28) and hematopoietic stem cell transplantation (HSCT, n=13) from 1992 to 2012. We compared the characteristics and estimated the survival outcomes according to several factors [age-adjusted-IPI (aaIPI), pathologic subtype, viral status, extranodal manifestation] and added some significant parameters to aaIPI scoring system. Post-HSCT-PTLD patients were younger and showed earlier onset, and viral status was more frequently identified. Ten-year OS of the entire group was 44% but the 10-year OS was not significantly different between post-KT-PTLD and post-HSCT-PTLD (39% vs. 56%, P=0.860). The time onset of PTLD and viral statuses were not meaningful, however, aaIPI, age>50, extranodal manifestation and monomorphic subtype were predictive for OS. We used those factors for PTLD-specific scoring which showed intermediate-risk (HR=7.1, P=0.019) and high-risk (HR=16.5, P=0.001) presented worse OS compared to low-risk subgroup. Although the treatment strategies were heterogenous, this study showed comprehensive PTLD data between KT versus HSCT, and our PTLD-specific scoring might be validated by another larger studies.
引用
收藏
页码:721 / 732
页数:12
相关论文
共 33 条
[1]   Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation [J].
Bakker, Nicolaas A. ;
van Imhoff, Gustaaf W. ;
Verschuuren, Erik A. M. ;
van Son, Willem J. .
TRANSPLANT INTERNATIONAL, 2007, 20 (03) :207-218
[2]   Rituximab in renal transplantation [J].
Barnett, A. Nicholas R. ;
Hadjianastassiou, Vassilis G. ;
Mamode, Nizam .
TRANSPLANT INTERNATIONAL, 2013, 26 (06) :563-575
[3]   Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry [J].
Caillard, S. ;
Lelong, C. ;
Pessione, F. ;
Moulin, B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (11) :2735-2742
[4]   Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study [J].
Choquet, S ;
Leblond, V ;
Herbrecht, R ;
Socié, G ;
Stoppa, AM ;
Vandenberghe, P ;
Fischer, A ;
Morschhauser, F ;
Salles, G ;
Feremans, W ;
Vilmer, E ;
Peraldi, MN ;
Lang, P ;
Lebranchu, Y ;
Oksenhendler, E ;
Garnier, JL ;
Lamy, T ;
Jaccard, A ;
Ferrant, A ;
Offner, F ;
Hermine, O ;
Moreau, A ;
Fafi-Kremer, S ;
Morand, P ;
Chatenoud, L ;
Berriot-Varoqueaux, N ;
Bergougnoux, L ;
Milpied, N .
BLOOD, 2006, 107 (08) :3053-3057
[5]   CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation [J].
Choquet, Sylvain ;
Trappe, Ralf ;
Leblond, Veronique ;
Jaeger, Ulrich ;
Davi, Frederic ;
Oertel, Stephan .
HAEMATOLOGICA, 2007, 92 (02) :273-274
[6]   Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants [J].
Davis, CL ;
Wood, BL ;
Sabath, DE ;
Joseph, JS ;
Stehman-Breen, C ;
Broudy, VC .
TRANSPLANTATION, 1998, 66 (12) :1770-1779
[7]  
Domingo-Domènech E, 2001, HAEMATOLOGICA, V86, P715
[8]   Lymphomas occurring late after solid-organ transplantation - Influence of treatment on the clinical outcome [J].
Dotti, G ;
Fiocchi, R ;
Motta, T ;
Mammana, C ;
Gotti, E ;
Riva, S ;
Cornelli, P ;
Gridelli, B ;
Viero, P ;
Oldani, E ;
Ferrazzi, P ;
Remuzzi, G ;
Barbui, T ;
Rambaldi, A .
TRANSPLANTATION, 2002, 74 (08) :1095-1102
[9]   Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era [J].
Evens, Andrew M. ;
David, Kevin A. ;
Helenowski, Irene ;
Nelson, Beverly ;
Kaufman, Dixon ;
Kircher, Sheetal M. ;
Gimelfarb, Alla ;
Hattersley, Elise ;
Mauro, Lauren A. ;
Jovanovic, Borko ;
Chadburn, Amy ;
Stiff, Patrick ;
Winter, Jane N. ;
Mehta, Jayesh ;
Van Besien, Koen ;
Gregory, Stephanie ;
Gordon, Leo I. ;
Shammo, Jamile M. ;
Smith, Scott E. ;
Smith, Sonali M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :1038-1046
[10]   Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen [J].
Fohrer, Cecile ;
Caillard, Sophie ;
Koumarianou, Argyro ;
Ellero, Bernard ;
Woehl-Jaegle, Marie-Lorraine ;
Meyer, Carole ;
Epailly, Eric ;
Chenard, Marie-Pierre ;
Lioure, Bruno ;
Natarajan-Ame, Shanti ;
Maloisel, Frederic ;
Lutun, Philippe ;
Kessler, Romain ;
Moulin, Bruno ;
Bergerat, Jean-Pierre ;
Wolf, Philippe ;
Herbrecht, Raoul .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (06) :602-612